Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function

Transplant International

Volumn 12, Issue 1, 1999, Pages 2-9

  Lange, Harald ^a   Müller, Thomas F ^a   Ebel, Horst ^a   Kuhlmann, Uwe ^a   Grebe, Scott O ^a   Heymanns, Jochen ^a   Feiber, Horst ^a   Riedmiller, Hubertus ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

ATG, delayed graft function, kidney transplantation; Delayed graft function, ATG, kidney transplantation; Induction therapy, ATG

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; METHYLPREDNISOLONE; POLYCLONAL ANTIBODY; STEROID; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; ANTILYMPHOCYTE SERUM; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOCYTE SUBSETS; MIDDLE AGED; MUROMONAB-CD3; POSTOPERATIVE COMPLICATIONS;

EID: 0344859877     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001470050178     Document Type: Article

References (27)

1. Abouna GM, Al-Abdullah IH, Kelly-Sullivan D, Kumar MSA, Loose J, Phillips K, Yost S, Seirka D (1995) Randomized clinical trial of antithymo-cyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T-cell monitoring. Transplantation 59: 1564-1568
2. Abramowicz D, Norman DJ, Vereerstraeten P, Goldman M, De Pauw L, Vanherweghem JL, Kinnaert P, Kahana L. Stuart FP Jr, Thistlethwaite JR Jr, Shield CF III, Monaco A, Wu SC, Haverty TP (1996) OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int 49: 768-772
3. Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landmann J, Thiel G (1995) A randomised prospective trial of prophylactic immuno-suppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation 59: 830-840
4. Cecka JM, Terasaki PI (eds) (1995) Clinical transplants. UCLA Tissue Typing Laboratory, Los Angeles, pp 1-728
5. Cockfield SM, Preiksaitis JK, Jewel LD, Parfrey NA (1993) Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 56: 88-96
6. Cosimi AB (1985) Treatment of rejection: antithymocyte globulin versus monoclonal antibodies. Transplant Proc 17: 1526-1529
7. Crosnier J, Kreis H, Descamps JM, Mansouri R (1980) Are there non-steroid-dependent rejection episodes? Proc EDTA 17: 391-395
8. Cutler SJ, Ederer FJ (1958) Maximum utilization of the life table method in analyzing survival. J Chron Dis 8: 699-712
9. Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, Dunn DL, Sutherland DER, Najarian JS (1992) Sequential therapy - a prospective randomized trial of MALG versus OKT3 for prophylactic immuno-suppressior in cadaver renal allograft recipients. Transplantation 54: 50-56
10. Grinyo JM, Gil-Vernet S, Moreso F, Seron D, Fulladosa X, Cruzado JM, Riera L, Anuneiada AJ, Hueso M, Alesina J (1996) Ischemic reperfusion injury as a risk factor for late kidney graft failure. In: Touraine JL, Traeger J, Bétuel H, Dubernard JM, Revillard JP, Dupuy C (eds) Late graft loss. Kluwer, Academic Publishers, Dordrecht, The Netherlands, pp 77-83
11. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, Delvecchio A, Delmonico FL, Auchincloss H, Rubin RH (1992) Symptomatic cytomegalovirus disease in the cytomegalovirus antibody sero-positive renal transplant recipient treated with OKT3. Transplantation 53: 68-72
12. Kaden J, May G, Strobelt V, Groth J, Müller P (1997) Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG-bolus as a new approach to improve long-term results after kidney transplantation. Transplant Proc 29: 344-347
13. Khana L, Ackermann J, Lefor W, et al (1990) Uses of Orthoclone OKT3 for prophylaxis of rejection and induction in initial nonfunction in kidney transplantation. Transplant Proc 22: 1755-1758
14. Kumar MS, Stephan R, Chui J, Brezin J, Lyons P, Katz SM, Abouna GM (1993) Comparative study of cadaver donor kidneys preserved in University of Wisconsin solution for less than or longer than 30 hours. Transplant Proc 25: 2265-2266
15. Kung P, Goldstein G, Reinherz E, Schlossman S (1979) Monoclonal antibodies defining distinctive human T-cell surface antigens. Science 206: 347-349
16. Lange H, Michalik R, Himmelmann GW (1989) Withdrawal of steroids after kidney transplantation - a prospective study.Transplant Proc 17: 2694-2696
17. Monaco A, Goldstein G, Barnes L (1987) Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immuno-suppressive regimens. Transplant Proc 19 [Suppl 1]:28-31
18. Müller TF, Grebe SO, Neumann MC, Heymanns J, Radsak K, Sprenger H, Lange H (1997) Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 64: 1432-1437
19. Norman DJ, Barry JM, Bennet WM, Leone M, Henell K, Funnell B, et al. (1988) The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy. Am J Kidney Dis 11: 90-93
20. Norman DJ, Kahana L, Stuart FP Jr, Thistlethwaite JR Jr, Shield CF III, Monaco A, Dehlinger J, Wu SC, Van Horn A, Haverty TP (1993) A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55: 44-50
21. Novick AC, Ho-Hsieh H, Steinmuller D, et al (1986) Detrimental effects of cyclosporine on initial function of cadaver renal allografts following extended preservation. Transplantation 42: 154-158
22. Olausson M, Wramner L, Kjellson B, Mjörnstedt L, Söderström T (1993) Alteration in T-cell subset phenotypes as cell markers for rejection of long-term allograft acceptance in allografted rats treated with antithymocyte globulin. Int Arch Allergy Immunol 101: 431-436
23. Sells RA, et al (1983) A prospective randomized substitutive trial of cyclosporine as a prophylactic agent in human renal transplant rejection. Transplant Proc 15 [Suppl 1]:279-84
24. Simpson MA, Monaco AP (1995) Clinical uses of polyclonal and monoclonal antilymphoid sera. In: Chatenoud L (ed) Monoclonal antibodies in transplantation. Landes, Texas, Landes pp 1-19
25. Steinmuller DR, Hayes JM, Novick AC, Streem SB, Hodge E, Slavis S, Martinez A, Graneto D, Pearce G (1991) Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation 52: 67-71
26. Thibaudin D, Alamartine E, DeFilippis JP, Diab N, Laurent B, Berthoux F (1996) Randomized prospective study comparing induction with and without antithymocyte globulins in immunized kidney allograft recipients (abstract). XVIth International Congress of the Transplantation Society, Barcelona, p 194
27. Vereerstraeten P, Dupont E, Andrien M, DePauw L, Abramowicz D, Goldman M, Kinnaert P (1995) Influence of donor-recipient HLA-DR mismatches and OKT3 prophylaxis on cadaver kidney graft survival. Transplantation 60: 253-258